Microbiome

Advantages and expertise for microbiome drug discovery

Gut microbiome: A significant target for therapeutics

Research in the last two decades has demonstrated the critical influence that the microbes in our gut have on our overall health. A perturbed gut microbiome is implicated in diverse disease states, and is a significant target for therapeutic intervention

C. elegans as a model for microbiome research

C. elegans is an established research model for studying the gut microbiome. Many factors including gut anatomy, human gene homology, a short life cycle and large population number make C. elegans a suitable model for testing the health effects of prebiotics, probiotics and postbiotics.

C. elegans have an intrinsic host-microbe interaction that can be used specifically for microbiome research. Worms feed naturally on bacteria, which can be exploited to study the effects of single microbe strains isolated from the human gut microbiome, bacterial extracts or conditioned media. Combined with our automated WormGazer^TM technology, and rich output of data, this confers several benefits for your project.

We elevate the intrinsic advantage of C. elegans for microbiome research with our expert knowledge and rich data output

Our advantage for microbiome drug discovery studies:

Rapidly test the acute and chronic effects of bacterial strains on multiple functional end-points relevant to human health and quality of life
Ability to distinguish the impact of your product in early-life, mid and late-adulthood
Rich customisable data with population-scale screening of products that target the gut microbiome
Consultancy from leading multidisciplinary experts for study design input
Automated Wormgazer^TM technology with high throughput and data reproducibility
A diverse range of functional assays that allow you to quickly understand the health benefits of your strains and differentiate them from your competitors
Target identification and transgenic approaches to understand mechanisms of action

“We have formed an incredible partnership, which not only has provided AB Biotek with novel information on our formulations, but also Magnitude Biosciences with new technology to implement in their future services. All of this will be reflected in the publications of several papers and the filing of several patents. We hope to maintain this collaboration in future projects and keep developing new formulations to help human health.”

Gerald Dard, Managing Director , AB Biotek HNH

Read the Case Study here

“Magnitude Biosciences has proven itself to be a world-leading C. elegans CRO. The team behind the project has been extremely flexible throughout every step of our collaboration, and has been extremely supportive and innovative when it comes to developing new technology to meet our needs. We are not C. elegans experts, but Magnitude Biosciences aided us in fully comprehending the data generated in our studies and ensuring that it was understandable for our particular needs.”

María Tintoré, senior scientist at AB Biotek HNH

Read the Case Study here